Associations - CD47 inhibitor

No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B	ONO-7913 Sensitive: B - Late Trials ONO-7913 Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	PT217 Sensitive: B - Late Trials PT217 Sensitive : B	PT217 Sensitive: B - Late Trials PT217 Sensitive : B
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	ONO-7913 Sensitive: C2 – Inclusion Criteria ONO-7913 Sensitive : C2	ONO-7913 Sensitive: C2 – Inclusion Criteria ONO-7913 Sensitive : C2
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + ONO-7913 Sensitive: C2 – Inclusion Criteria venetoclax + ONO-7913 Sensitive : C2	venetoclax + ONO-7913 Sensitive: C2 – Inclusion Criteria venetoclax + ONO-7913 Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	D3L-001 Sensitive: C2 – Inclusion Criteria D3L-001 Sensitive : C2	D3L-001 Sensitive: C2 – Inclusion Criteria D3L-001 Sensitive : C2
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	IMM0306 Sensitive: C2 – Inclusion Criteria IMM0306 Sensitive : C2	IMM0306 Sensitive: C2 – Inclusion Criteria IMM0306 Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3	trastuzumab + ramucirumab + ALX148 Sensitive: C3 – Early Trials trastuzumab + ramucirumab + ALX148 Sensitive : C3
CD20 positive	Non-Hodgkin’s Lymphoma	CD20 positive	Non-Hodgkin’s Lymphoma	rituximab + ALX148 Sensitive: C3 – Early Trials rituximab + ALX148 Sensitive : C3	rituximab + ALX148 Sensitive: C3 – Early Trials rituximab + ALX148 Sensitive : C3
PD-L1 expression	Small Cell Lung Cancer	PD-L1 expression	Small Cell Lung Cancer	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3
MRC1 expression	Small Cell Lung Cancer	MRC1 expression	Small Cell Lung Cancer	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	ALX148 Sensitive: C3 – Early Trials ALX148 Sensitive : C3	ALX148 Sensitive: C3 – Early Trials ALX148 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	ONO-7913 Sensitive: C3 – Early Trials ONO-7913 Sensitive : C3	ONO-7913 Sensitive: C3 – Early Trials ONO-7913 Sensitive : C3
TP53 wild-type	Myelodysplastic Syndrome	TP53 wild-type	Myelodysplastic Syndrome	ONO-7913 Sensitive: C3 – Early Trials ONO-7913 Sensitive : C3	ONO-7913 Sensitive: C3 – Early Trials ONO-7913 Sensitive : C3
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3
CD20 positive	Marginal Zone Lymphoma	CD20 positive	Marginal Zone Lymphoma	IMM0306 Sensitive: C3 – Early Trials IMM0306 Sensitive : C3	IMM0306 Sensitive: C3 – Early Trials IMM0306 Sensitive : C3
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab + ONO-7913 Sensitive: C3 – Early Trials atezolizumab + ONO-7913 Sensitive : C3	atezolizumab + ONO-7913 Sensitive: C3 – Early Trials atezolizumab + ONO-7913 Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + ONO-7913 Sensitive: D – Preclinical trastuzumab + ONO-7913 Sensitive : D	trastuzumab + ONO-7913 Sensitive: D – Preclinical trastuzumab + ONO-7913 Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	SRF231 Sensitive: D – Preclinical SRF231 Sensitive : D	SRF231 Sensitive: D – Preclinical SRF231 Sensitive : D
EGFR H1975	Non Small Cell Lung Cancer	EGFR H1975	Non Small Cell Lung Cancer	SRF231 Sensitive: D – Preclinical SRF231 Sensitive : D	SRF231 Sensitive: D – Preclinical SRF231 Sensitive : D
CD47 overexpression + CD38 underexpression	Multiple Myeloma	CD47 overexpression + CD38 underexpression	Multiple Myeloma	ABBV-IMAB-TJC4 + MOR202 Sensitive: D – Preclinical ABBV-IMAB-TJC4 + MOR202 Sensitive : D	ABBV-IMAB-TJC4 + MOR202 Sensitive: D – Preclinical ABBV-IMAB-TJC4 + MOR202 Sensitive : D
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	disitamab vedotin + ABBV-IMAB-TJC4 Sensitive: D – Preclinical disitamab vedotin + ABBV-IMAB-TJC4 Sensitive : D	disitamab vedotin + ABBV-IMAB-TJC4 Sensitive: D – Preclinical disitamab vedotin + ABBV-IMAB-TJC4 Sensitive : D
TPBG expression	Solid Tumor	TPBG expression	Solid Tumor	YH38560 Sensitive: D – Preclinical YH38560 Sensitive : D	YH38560 Sensitive: D – Preclinical YH38560 Sensitive : D
CD47 expression	Solid Tumor	CD47 expression	Solid Tumor	YH38560 Sensitive: D – Preclinical YH38560 Sensitive : D	YH38560 Sensitive: D – Preclinical YH38560 Sensitive : D
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	IMM2902 Sensitive: D – Preclinical IMM2902 Sensitive : D	IMM2902 Sensitive: D – Preclinical IMM2902 Sensitive : D
PD-L1 expression + CD47 expression	Colon Cancer	PD-L1 expression + CD47 expression	Colon Cancer	NI-2901 Sensitive: D – Preclinical NI-2901 Sensitive : D	NI-2901 Sensitive: D – Preclinical NI-2901 Sensitive : D
CD47 expression + EPCAM expression	Small Cell Lung Cancer	CD47 expression + EPCAM expression	Small Cell Lung Cancer	VBI-003 Sensitive: D – Preclinical VBI-003 Sensitive : D	VBI-003 Sensitive: D – Preclinical VBI-003 Sensitive : D
CD47 expression + EPCAM expression	Colorectal Cancer	CD47 expression + EPCAM expression	Colorectal Cancer	VBI-003 Sensitive: D – Preclinical VBI-003 Sensitive : D	VBI-003 Sensitive: D – Preclinical VBI-003 Sensitive : D
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	D3L-001 Sensitive: D – Preclinical D3L-001 Sensitive : D	D3L-001 Sensitive: D – Preclinical D3L-001 Sensitive : D
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pertuzumab + D3L-001 Sensitive: D – Preclinical pertuzumab + D3L-001 Sensitive : D	pertuzumab + D3L-001 Sensitive: D – Preclinical pertuzumab + D3L-001 Sensitive : D

CD47 inhibitor

CD47 inhibitor

Associations(37)

Associations
(37)